Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry

被引:56
作者
Vidal-Laliena, M
Romero, X
March, S
Requena, V
Petriz, J
Engel, P
机构
[1] Univ Barcelona, Sch Med, Dept Cellular Biol & Pathol, Immunol Unit,Inst Invest Biomed August Pi & Sunye, E-08036 Barcelona, Spain
[2] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Cryopreservat Unit, E-08036 Barcelona, Spain
关键词
leukocytes; B cells; cell-surface molecules; monoclonal antibodies; CD;
D O I
10.1016/j.cellimm.2005.08.002
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The aim of this study was to characterize the reactivity of monoclonal antibodies (mAbs) that had been submitted to the HLDA8 Workshop. The lineage specificity of target molecules was tested by analyzing their expression patterns on blood cells, leukocytes, and lymphocyte subsets. The expression of target molecules during B cell development, ranging from early precursors to plasma cells, was analyzed using a large panel of B cell lines. Our results have permitted us to characterize the expression of 10 new CD molecules: CD316 (HM1.24, BST2), CD268 (BAFF-R, TNFRSF13C), CD269 (BCMA, TNFRF17), CD267 (TACI, TNFRSF13B), CD275 (ICOSL, B7H2), CD254 (TRANCE, TNFSF11), CD252 (OX40L TNFSF4), CD315 (CD9-P), CD316 (EWI-2, PGRL), and CD307 (IRTA-2 or FcRH5). Three of these new CDs, CD267, CD269, and CD307 presented a B cell-restricted expression pattern. MAbs against these novel cell-surface molecules may offer new tools for research, diagnosis, and therapy. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:6 / 16
页数:11
相关论文
共 33 条
[1]   BAFF selectively enhances the survival of plasmablasts generated from human memory B cells [J].
Avery, DT ;
Kalled, SL ;
Ellyard, JI ;
Ambrose, C ;
Bixler, SA ;
Thien, M ;
Brink, R ;
Mackay, F ;
Hodgkin, PD ;
Tangye, SG .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02) :286-297
[2]  
BARCLEY AN, 1997, LEUCOCYTE ANTIGEN FA
[3]   EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells [J].
Charrin, S ;
Le Naour, F ;
Labas, V ;
Billard, M ;
Le Caer, JP ;
Emile, JF ;
Petit, MA ;
Boucheix, C ;
Rubinstein, E .
BIOCHEMICAL JOURNAL, 2003, 373 :409-421
[4]   The major CD9 and CD81 molecular partner - Identification and characterization of the complexes [J].
Charrin, S ;
Le Naour, F ;
Oualid, M ;
Billard, M ;
Faure, G ;
Hanash, SM ;
Boucheix, C ;
Rubinstein, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (17) :14329-14337
[5]  
CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97
[6]  
CLARK EA, 2002, LEUCOCYTE TYPING, V7, P81
[7]   PGRL is a major CD81-associated protein on lymphocytes and distinguishes a new family of cell surface proteins [J].
Clark, KL ;
Zeng, ZH ;
Langford, AL ;
Bowen, SM ;
Todd, SC .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :5115-5121
[8]   Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].
Croucher, PI ;
Shipman, CM ;
Lippitt, J ;
Perry, M ;
Asosingh, K ;
Hijzen, A ;
Brabbs, AC ;
van Beek, EJR ;
Holen, I ;
Skerry, TM ;
Dunstan, CR ;
Russell, GR ;
Van Camp, B ;
Vanderkerken, K .
BLOOD, 2001, 98 (13) :3534-3540
[9]   Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family [J].
Davis, RS ;
Dennis, G ;
Odom, MR ;
Gibson, AW ;
Kimberly, RP ;
Burrows, PD ;
Cooper, MD .
IMMUNOLOGICAL REVIEWS, 2002, 190 (01) :123-136
[10]   Evidence of a role for RANKL in the development of myeloma bone disease [J].
De Leenheer, E ;
Mueller, GS ;
Vanderkerken, K ;
Croucher, PI .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :340-346